- Home
- UPB vs LIMN Comparison
UPB vs LIMN Comparison
Compare UPB & LIMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UPB
- LIMN
- Stock Information
- Founded
- UPB 2021
- LIMN 2018
- Country
- UPB United States
- LIMN United States
- Employees
- UPB N/A
- LIMN N/A
- Industry
- UPB
- LIMN
- Sector
- UPB
- LIMN
- Exchange
- UPB NYSE
- LIMN NYSE
- Market Cap
- UPB 823.6M
- LIMN 623.8M
- IPO Year
- UPB 2024
- LIMN N/A
- Fundamental
- Price
- UPB $15.54
- LIMN $5.93
- Analyst Decision
- UPB Strong Buy
- LIMN
- Analyst Count
- UPB 4
- LIMN 0
- Target Price
- UPB $56.50
- LIMN N/A
- AVG Volume (30 Days)
- UPB 434.2K
- LIMN 987.0K
- Earning Date
- UPB 08-14-2025
- LIMN 01-01-0001
- Dividend Yield
- UPB N/A
- LIMN N/A
- EPS Growth
- UPB N/A
- LIMN N/A
- EPS
- UPB N/A
- LIMN N/A
- Revenue
- UPB $2,296,000.00
- LIMN N/A
- Revenue This Year
- UPB N/A
- LIMN N/A
- Revenue Next Year
- UPB N/A
- LIMN N/A
- P/E Ratio
- UPB N/A
- LIMN N/A
- Revenue Growth
- UPB N/A
- LIMN N/A
- 52 Week Low
- UPB $5.14
- LIMN $4.40
- 52 Week High
- UPB $29.46
- LIMN $33.66
- Technical
- Relative Strength Index (RSI)
- UPB N/A
- LIMN N/A
- Support Level
- UPB N/A
- LIMN N/A
- Resistance Level
- UPB N/A
- LIMN N/A
- Average True Range (ATR)
- UPB 0.00
- LIMN 0.00
- MACD
- UPB 0.00
- LIMN 0.00
- Stochastic Oscillator
- UPB 0.00
- LIMN 0.00
About UPB UPSTREAM BIO INC
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.
About LIMN LIMINATUS PHARMA INC
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing cancer therapies and treatments. The GCC Vaccine of the company is in Phase II of clinical trials designed for immune behavior towards colorectal, pancreatic, gastric, and esophageal cancers that express Guanylyl Cyclase C.